Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
There are telltale budgeting mistakes to watch for. Identify them early and apply straightforward fixes to stay on target.
21,987 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
In a volatile market, a strategically chosen oil major could outperform the S&P 500 in the latter half of 2026. This ...
If you are weighing where to invest in the chip sector, this article breaks down how Intel and TSMC differ, what that...
When Wells Fargo reports earnings, the spotlight isn’t just on per-share figures. The real story this quarter is net ...
Amazon’s chip initiative is quietly redefining cloud economics. This article breaks down the numbers, the tech stack,...
As 2026 unfolds, investors must weigh software-driven growth against hardware resilience. This guide compares Salesfo...
Palantir has surprised and divided investors with big moves and bold AI promises. This guide explains what to watch, ...
Amazon ends Walmart’s long hold on the Fortune 500 top spot, posting 2025 revenue of $716.9 billion to Walmart’s $713...
When a former chief officer sells stock, investors should look beyond the headline. This guide explains why insider m...
Bridger Management quietly exited a large Bath & Body Works position in the fourth quarter, selling about 301,000 sha...
A major hedge fund recently boosted its Garrett Motion position, highlighting how hybrid powertrain trends are reshap...
A Wayfair co-founder recently sold a substantial stake, signaling a strategic portfolio reshuffle amid ambitious expa...